study designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study will
measure the immune response to this vaccine in an animal model in anticipation of clinical test in
humans.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, February 28, 2020 11:57 AM

To: Fauci, Anthony (NIH/NIAID) (EJ) >; Auchincloss, Hugh (NIH/NIAID) (E]
0) 6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) (€] (>; Harper, Jill (NIH/NIAID) 3) EL 1 |
Crum, Wayne (NIH/NIAID) [E]] (b) (6F

Ce: Eisinger, Robert (NIH/NIAID) >>; Folkers, Greg (NIH/NIAID) (E]
C0) >; Conrad, Patricia (NIH/NIAID) (Ef) > Marston,
Hilary (NIH/NIAID) 7 SION Lerner, Andrea (NIH/NIAID) [E]
CC) (6J>; Gilles, Sharon (NIH/NIAID) [EJS >; Routh, Jennifer
(NIH/NIAID} [E][-________— 1 @)>; Stover, Kathy (NIH/NIAID) [E][-________©@>; Law,
Kim (NIH/NIAID) (E]fL_, ©) @J>; Lee, Kun-Lin (NIH/NIAID) [EJZ YF

Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27/20

 

 

Tony,

Since we our last report we have increased spending on the COVID-19 response by $2.3M for a
total YTD spending of $12.4M.

A recap of the $2.3 million spent in the last week is as follows:
e $1.9M to set-up a Phase I trial (45 subjects) of the VRC/Moderna mRNA platform
candidate at Kaiser Permanente Washington Health Research Institute (One of the
VTEUs)
